Thalidomide Use in the US
- 1 January 2006
- journal article
- Published by Springer Nature in Drug Safety
- Vol. 29 (4) , 321-329
- https://doi.org/10.2165/00002018-200629040-00003
Abstract
Introduction:In 1998, thalidomide (Thalomid®), a known human teratogen, was approved by the US FDA for the treatment of erythema nodosum leprosum. To prevent fetal exposure to thalidomide, a...Keywords
This publication has 11 references indexed in Scilit:
- ACOG committee opinion #278: avoiding inappropriate clinical decisions based on false-positive human chorionic gonadotropin test resultsPublished by Wolters Kluwer Health ,2002
- False-positive serum human chorionic gonadotropin results: Causes, characteristics, and recognitionAmerican Journal of Obstetrics and Gynecology, 2002
- Thalomid?? (Thalidomide) CapsulesDrug Safety, 2001
- False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrationsThe Lancet, 2000
- S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomideClinical Therapeutics, 1999
- Gestational trophoblastic diseaseCancer, 1995
- Measuring human chorionic gonadotropin for detection of early pregnancy lossReproductive Toxicology, 1988
- Further observations on serial human chorionic gonadotropin patterns in ectopic pregnancies and spontaneous abortionsFertility and Sterility, 1988
- Thalidomide embryopathy.1962
- Thalidomide EmbryopathyArchives of environmental health, 1962